and the Global Strategy to End Preventable Maternal Mortality (EPMM), 1, 2 improving the measurement of maternal health will be key. Building on the success of the WHO in defining and measuring maternal near-miss events, 3 which also established parameters for quality of care for severe maternal complications/morbidities, action is now focused on standardizing and measuring non-life-threatening maternal morbidity.
As maternal mortality trends downward, measuring morbidity will be critical to monitoring the quality of maternal health care. Based on previous efforts of the WHO Department of Reproductive Health and Research (RHR) to standardize the measurement and reporting of maternal mortality and severe maternal morbidity, efforts are expanding to also address measurement of non-life-threatening (nonsevere) maternal morbidity, especially given that the often-cited maternal morbidity estimate of around 20-30 morbidities for every maternal death is "not based on standard, well documented, and transparent methodologies". 4 RHR implemented a 5-year project to address the lack of a scientific basis for defining, estimating, and monitoring the magnitude of maternal morbidity. It was envisioned that in addition to standardizing what is called maternal morbidity and how it is measured, doing so would not only assist program managers and policy makers to better monitor maternal morbidity, but it would also bring attention and resources to enhancing care for pregnant and postpartum women. The present paper describes the initial performance of this new set of standardized maternal morbidity measurement tools, and represents the final step in a larger initiative (described in the methods section) that seeks to advocate for and improve women's health.
The pilot study sought to field test a comprehensive instrument to measure nonsevere morbidity among women in antenatal care (ANC) and postpartum care (PPC). The paper presents study findings and insights into its future use. Subobjectives included:
1. Describing the sociodemographic characteristics of the women recruited, by country.
Examining the contributory factors and clinical indicators identified
and their relationship to obstetric and medical diagnoses among pregnant and postpartum women.
3.
Exploring the feasibility and challenges associated with administering the instrument (for research purposes only).
| MATERIALS AND METHODS
This study is the culmination of a 5-year initiative led by the Maternal Morbidity Working Group (MMWG) convened by RHR, the details of which have been published elsewhere. [4] [5] [6] In brief, the group, composed of technical experts in maternal and women's health, began by defining non-life-threatening (hereafter referred to as nonsevere) maternal morbidities as: "Any health condition attributed to and/or complicating pregnancy and childbirth that has a negative impact on the woman's wellbeing and/or functioning". 4 To operationalize this definition, a maternal morbidity matrix was developed. 4 It outlined three dimensions: (1) To field test the instruments, a cross-sectional study was conducted in three countries (Jamaica, Kenya, and Malawi) in late 2015 to early 2016, over 3-month periods in each country. All sites (n=13)
were public facilities: nine in Jamaica (6 health centers and 3 referral hospitals), three in Kenya (2 district and 1 referral hospital), and one in Malawi (referral hospital). Efforts were made to include a range of facilities (primary, secondary, and tertiary referral facilities; in urban and rural settings) from different subnational areas, although the choice also depended on availability of the relevant resources to ensure highquality data collection. Ethical approval was obtained from the WHO Ethical Review Committee and relevant entities in each country. To describe the different types of morbidity, and enable stratification by country setting and time of administration, a sample size of 500 women per country (250 each, ANC and PPC) was calculated to be adequate. Without pooling data across sites or populations, we estimated a 6% margin of error.
Participants were conveniently selected from among women presenting for routine ANC or PPC services. Inclusion criteria were that ANC women were at least 28 weeks pregnant, and PPC women were 6-12 weeks after delivery. 15 Women whose pregnancies ended in abortion or miscarriage were excluded, while those who experienced stillbirths were included. Women provided written informed consent before being interviewed.
Health professionals (nurses, midwives, or doctors, depending on the site) participated in a 2-day training session to administer the ANC and PPC instruments. They were informed about the study objectives, introduced to the instruments, learned how to use the digital tablets, and gained practical experience before final selection. A manual detailing standard operating procedures for each question was developed and modified for each country. In Jamaica and Kenya, the interviewers were facility staff recruited for this proj- 
| RESULTS
Interviews were conducted with 1490 women (750 ANC; 740 PPC).
Sixteen ANC and 39 PPC women declined to participate. While similar to the study population, ANC refusers were older (27.6 ± 8. 
P<0
.001) were recruited from referral sites to ensure that the instrument could be tested on women with a morbid condition in pregnancy and the puerperium.
In expanding the definition of morbidity, selected contributory factors were explored. We examined exposure to violence by asking women whether they had been "afraid of your current/most recent husband or partner or anyone else," or whether "since pregnancy/ delivery, was there ever a time when you were pushed, slapped, hit, site from 7% to 17%. We also explored substance use through selfreporting (3%-4% overall; Table 3 ) and, given the global prevalence of obesity, women's heights and weights were documented ( While time and resources did not permit a rigorous qualitative evaluation of the feasibility and challenges associated with administering the tools for research purposes, we did discuss the process with data collectors at feedback meetings. The relatively low refusal rate was an indication that women were willing to participate in the process. During discussions with data collectors to determine the feasibility and challenges of implementing the tool, it became clear that while women were open to talking about difficult topics (violence, mental health, and sexual satisfaction) that were not generally associated with routine care, interviewers (trained health workers) felt unprepared to engage in these discussions, or were concerned that there were inadequate referral services for women presenting with these issues/ conditions. Interviewers did agree, however, that these were important issues and need to be considered in future clinical interactions with women, especially the issue of depression.
| DISCUSSION
The MMWG's efforts have led to the development of a measurement instrument to describe nonsevere maternal morbidity in a manner that highlights the woman's experience of pregnancy as the starting point. Its woman-centered questions have allowed for self-reporting 15 of factors contributing to morbidity. The instrument is then strengthened by the clinical perspective through diagnoses by skilled providers. The pilot study aimed to field test this T A B L E 2 Characteristics of the postpartum care study population. comprehensive instrument, which aims to standardize the measurement of nonsevere morbidity among antenatal and postpartum women. The piloted instrument measured morbidity more broadly by incorporating a wide range of self-reported factors, beginning with symptoms, contributing factors, and ability to carry out daily activities (functioning). Additionally, based on study results, we described the sociodemographic characteristics of participating women, as well as estimating both contributory factors and the prevalence of maternal morbidities/conditions, and their relationship. These represent areas for further exploration and strategic development.
Of the approximately 210 million pregnancies that occur every year, around 303 000 culminate in a maternal death, yet there is no consensus on how many women suffer non-life-threatening complications, 16 ,17 probably due to the wide variety of previous definitions. 18, 19 Additionally, Koblinsky et al. 20 have described the reliability issues associated with self-reporting versus diagnoses by community or skilled care providers ("gold standard"). Our findings depict a similar phenomenon, where women's reported exposures yielded higher prevalence rates than those based on clinical assessment alone, such as when mental health and exposure to violence were evaluated.
We believe that addressing symptoms and conditions that women identify as rendering them less able to function, or causing significant discomfort, will be fundamental to addressing nonsevere maternal morbidity. The challenge, in a setting with limited resources, is to improve the health and social service system's capacity to respond to the demand for care that identifying and addressing these issues may require. As such, the purpose of the instrument needs to be clear for users, and its design should allow persons to utilize those components that address their needs. The instrument may need to be designed in modules that measure separately those clinical problems that health systems should be prepared to assist patients to manage, and issues for investigation by specifically interested researchers. However, this approach might sideline issues women deem important by relegating certain issues to lower priority. c Defined as use of the following substances: tobacco products, alcoholic beverages, marijuana (ganja), inhalants. d Women who responded no or never to the following questions: (1) Are you afraid of your current/most recent husband or partner or anyone else? Would you say never, sometimes, many times, most/all of the time?; (2) Since pregnancy/delivery, was there ever a time when you were pushed, slapped, hit, kicked, or beaten by (any of) your husband/partner(s) or anyone else? Research has shown that the prevalence of physical violence varies significantly by setting. Rates are generally higher (15%-71%), however, than those found in our study.
14 This may be due to the tool having only two screening questions, and to their broad scope. When women are asked specific questions about their experience with violence, rather than more general questions (i.e. "are you afraid…?"), they are more likely to respond affirmatively. Yet it is relevant to address exposure to violence, especially intimate partner violence, as it has been linked to poor ANC utilization, 23 low birth weight, and preterm delivery, 24 and possibly pregnancy-associated suicide and homicide. 25 T A B L E 5 Health status reported by women attending antenatal and postpartum care visits. Similarly, our clinical examination, and self-reporting of depression and anxiety (using GAD-7 and PHQ-9 for screening), documented a low prevalence. In many settings, mental health concerns are highly stigmatized. Cases may be missed as patients may somaticize these concerns through vague symptoms such as fatigue. 26 A Ghanaian study utilizing the PHQ in a postnatal population found a rate (3.5%; 95% CI, 3.2-3.7) that mirrored the one in our Jamaican population (3.5%; 95% CI, 1.3-5.8). 27 Many social and economic factors have been linked to antenatal and postnatal depression, including experiencing a first pregnancy, 28 being unmarried, 29 exposure to intimate partner violence, 30 and lack of partner/baby father support, 31 or of family cohesion. 28 Identifying and treating these mothers is critical not only to their health but also to the survival and development of their infants. 32 The documented rates require refocusing ANC and PPC services to ensure that these women receive appropriate care.
Limitations of the pilot study included a nonrepresentative sample population, especially in Kenya and Malawi, which was drawn from large urban hospitals. Given this relatively healthy population of women, we had to aggregate many diagnoses, as numbers were too small to separate specific diagnoses. The instrument does not include questions addressing the baby's signs and symptoms, or complications of labor and delivery, which may also help identify morbidity in mothers. Additionally, we were unable to follow the same women over time to measure the temporality of conditions, or distinguish between conditions that developed during pregnancy and prior to pregnancy (i.e. women diagnosed with diabetes mellitus were aggregated into the gestational diabetes mellitus category, as most are first tested and diagnosed during pregnancy). While the current instrument's focus on women's health-related functioning is important, it lacks a wellbeing component to illuminate how women interpret the experience of pregnancy, and how they feel about their health.
The pilot study presents a novel approach to measuring nonsevere maternal morbidity, and furthers the work of WHO and the MMWG to standardize the definition, identification, and measurement process. This holistic approach to assessing maternal morbidity will provide a basis for advocacy for women's health and rights in the broader context. 33 Further research is needed to validate the instrument, and to ensure that the data collected can be used to assess and improve maternal care, especially postpartum visits and continuing health care for women. This is consistent with the EPMM strategy to "address all causes of maternal mortality, reproductive and maternal morbidities and related disabilities" 2 and aligns with the progress needed to 
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